UNSPSC 51182046: Roxibolone

This classification denotes an anabolic steroid with the molecular formula C21H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3R7NLP419C, chemically known as 11beta,17beta-dihydroxy-17-methyl-3-oxoandrosta-1,4-diene-2-carboxylic acid but generally known as roxibolone, which bears US NIH Compound Identifier 68795. European Medicines Agency schedules Roxibolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10397MIG.

UNSPSC 51182046 Roxibolone, a Commodity code, represents pharmaceutical manufacturing and supply under multistate cooperative purchasing frameworks that aggregate demand across state and local government health systems. State and local governments buy roxibolone and similar generic pharmaceuticals through volume-purchase agreements negotiated by cooperative alliances, with pricing structures tied to authorized wholesale distribution networks and compliance with federal manufacturing and supply-chain security standards. Issuing bodies soliciting under this code include state purchasing offices administering multistate cooperatives on behalf of participating state agencies, local health departments, and municipalities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a primary buyer consolidating pharmaceutical needs across multiple participating states including Oregon.

Recent activity centers on the MMCAP Generic Multi Source Pharmaceuticals and OTC Products RFP (Solicitation S1070000015802), posted January 20, 2026, with proposal due date March 26, 2026. MMCAP seeks manufacturers to supply roxibolone and related generic pharmaceuticals under a two-year contract (with optional extensions through June 30, 2028) effective July 1, 2026, with products distributed through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must meet current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with at least two of the three authorized wholesalers, and accept a 3 percent administrative fee on all purchases. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 5 percent each on administrative fee format compliance, EDI capability, and willingness to accept the 3 percent fee. No specific set-aside designations are noted in the available documentation.